» Articles » PMID: 30369318

Association Between Statin Use and Cardiovascular Events After Carotid Artery Revascularization

Overview
Date 2018 Oct 30
PMID 30369318
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background Statins are commonly used for the prevention of cardiovascular events; however, statins are underutilized in patients with noncoronary atherosclerosis. We sought to establish the rates of statin use in patients with carotid artery disease and to examine the association between statin therapy and outcomes after carotid revascularization. Methods and Results In this population-level retrospective cohort study, we identified all individuals aged ≥66 years who underwent carotid endarterectomy or stenting in Ontario, Canada (2002-2014). The primary outcome was a composite of 1-year stroke, myocardial infarction, or death (major adverse cardiac and cerebrovascular events). Five-year risks were also examined. Adjusted hazard ratios were computed using inverse probability of treatment weighting based on propensity scores. A total of 7893 of 10 723 patients (73.6%) who underwent carotid revascularization were on preprocedural statin therapy; moderate- or high-dose therapy was utilized by 7384 patients (68.9%). The composite rate of 1-year major adverse cardiac and cerebrovascular events was lower among statin users (adjusted hazard ratio: 0.76; 95% confidence interval, 0.70-0.83). Patients who were on persistent long-term statin therapy after the carotid procedure continued to experience significantly lower risk of major adverse cardiac and cerebrovascular events at 5 years (adjusted hazard ratio: 0.75, 95% confidence interval, 0.71-0.80). The beneficial associations with statin use were observed regardless of type of carotid revascularization procedure, carotid artery symptom status, or statin dose. Conclusions Continuous statin therapy was associated with a 25% lower risk of long-term adverse cardiovascular events in patients with significant carotid disease. Along with other supportive evidence, statins should be considered in patients undergoing carotid revascularization, and efforts are required to increase statin use in this undertreated population.

Citing Articles

Appropriateness of care: Asymptomatic carotid stenosis including transcarotid artery revascularization.

Columbo J, Stone D Semin Vasc Surg. 2024; 37(2):179-187.

PMID: 39151997 PMC: 11330557. DOI: 10.1053/j.semvascsurg.2024.03.002.


Effect modification by statin use status on the association between fine particulate matter (PM2.5) and cardiovascular mortality.

Bai L, Kwong J, Kaufman J, Benmarhnia T, Chen C, van Donkelaar A Int J Epidemiol. 2024; 53(4).

PMID: 38961644 PMC: 11222296. DOI: 10.1093/ije/dyae084.


FRAX predicts cardiovascular risk in women undergoing osteoporosis screening: the Manitoba bone mineral density registry.

Ye C, Schousboe J, Morin S, Lix L, McCloskey E, Johansson H J Bone Miner Res. 2024; 39(1):30-38.

PMID: 38630880 PMC: 11207923. DOI: 10.1093/jbmr/zjad010.


Discharge prescription patterns for antiplatelet and statin therapy following carotid endarterectomy: an analysis of the vascular quality initiative.

Eppler M, Singh N, Ding L, Magee G, Garg P BMJ Open. 2023; 13(7):e071550.

PMID: 37491096 PMC: 10373683. DOI: 10.1136/bmjopen-2022-071550.


Association between lipid profile changes and risk of in-stent restenosis in ischemic stroke patients with intracranial stenosis: A retrospective cohort study.

Ryu J, Bae J, Ha S, Kwon B, Song Y, Lee D PLoS One. 2023; 18(5):e0284749.

PMID: 37163551 PMC: 10171672. DOI: 10.1371/journal.pone.0284749.


References
1.
Kennedy J, Quan H, Buchan A, Ghali W, Feasby T . Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke. 2005; 36(10):2072-6. DOI: 10.1161/01.STR.0000183623.28144.32. View

2.
Takayama K, Taki W, Toma N, Nakahara I, Maeda M, Tanemura H . Effect of pitavastatin on preventing ischemic complications with carotid artery stenting: a multicenter prospective study--EPOCH-CAS study. Cardiovasc Intervent Radiol. 2013; 37(6):1436-43. DOI: 10.1007/s00270-013-0813-x. View

3.
LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J . Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005; 352(14):1425-35. DOI: 10.1056/NEJMoa050461. View

4.
Kumbhani D, Steg P, Cannon C, Eagle K, Smith Jr S, Goto S . Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35(41):2864-72. PMC: 4216432. DOI: 10.1093/eurheartj/ehu080. View

5.
Chan A, Bhatt D, Chew D, Reginelli J, Schneider J, Topol E . Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003; 107(13):1750-6. DOI: 10.1161/01.CIR.0000060541.18923.E9. View